Bristol-Myers Squibb's Opdivo flunks late-stage lung cancer study

|About: Bristol-Myers Squibb C... (BMY)|By:, SA News Editor

An open-label Phase 3 clinical trial, CheckMate-331, evaluating Bristol-Myers Squibb's (NYSE:BMY) Opdivo (nivolumab) versus standard-of-care chemo (topotecan or amrubicin) in patients with relapsed small cell lung cancer (SCLC) failed to achieve the primary endpoint of overall survival (OS).

Other studies in SCLC are either ongoing or about to start, including a Phase 2 evaluating Opdivo + Yervoy (ipilimumab) in patients who have previously received platinum-based chemo.

Subscribe for full text news in your inbox